AlzeCure Pharma AB (publ)

Stockholm Stock Exchange ALZCUR.ST

AlzeCure Pharma AB (publ) Current Liabilities for the year ending December 31, 2023

AlzeCure Pharma AB (publ) Current Liabilities is NA for the year ending December 31, 2023. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • AlzeCure Pharma AB (publ) Current Liabilities for the year ending December 31, 2022 was USD 988.81 K.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
SV Wall Street
Stockholm Stock Exchange: ALZCUR.ST

AlzeCure Pharma AB (publ)

CEO Mr. Martin Jönsson
IPO Date Nov. 28, 2018
Location Sweden
Headquarters HAelsovAegen 7
Employees 11
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.

StockViz Staff

February 6, 2025

Any question? Send us an email